Thomas V. Riley

18.3k total citations · 3 hit papers
353 papers, 13.5k citations indexed

About

Thomas V. Riley is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Thomas V. Riley has authored 353 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 247 papers in Infectious Diseases, 143 papers in Epidemiology and 47 papers in Molecular Biology. Recurrent topics in Thomas V. Riley's work include Clostridium difficile and Clostridium perfringens research (216 papers), Microscopic Colitis (108 papers) and Viral gastroenteritis research and epidemiology (95 papers). Thomas V. Riley is often cited by papers focused on Clostridium difficile and Clostridium perfringens research (216 papers), Microscopic Colitis (108 papers) and Viral gastroenteritis research and epidemiology (95 papers). Thomas V. Riley collaborates with scholars based in Australia, United Kingdom and United States. Thomas V. Riley's co-authors include Christine Carson, Katherine A. Hammer, Daniel R. Knight, Brian J. Mee, Barbara J. Chang, Claudia Slimings, Deirdre A. Collins, Briony Elliott, David L. Paterson and R.A. Bowman and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Thomas V. Riley

340 papers receiving 12.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanism of Action ofMelaleuca alternifolia(Tea Tree) Oil onStaphylococcus aureusDetermined by Time-Kill, Lysis, Leakage, and Salt Tolerance Assays and Electron Microscopy

2002 775 citations Christine Carson, Brian J. Mee et al. profile →
Antimicrobial activity of the major components of the essential oil of Melaleuca alternifolia

1995 517 citations Christine Carson, Thomas V. Riley profile →
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis

2013 424 citations Claudia Slimings, Thomas V. Riley Journal of Antimicrobial Chemotherapy profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Thomas V. Riley	7.3k	4.2k	2.7k	2.6k	1.4k	353	13.5k
Rafael Cantón	7.0k 1.0×	8.4k 2.0×	2.2k 0.8×	5.6k 2.2×	942 0.7×	759	30.4k
Jordi Vilà	3.2k 0.4×	4.6k 1.1×	2.5k 0.9×	5.2k 2.0×	521 0.4×	540	20.1k
Maurizio Sanguinetti	9.6k 1.3×	7.8k 1.8×	1.1k 0.4×	4.4k 1.7×	754 0.5×	585	18.9k
David C. Hooper	5.3k 0.7×	4.8k 1.1×	2.1k 0.8×	6.7k 2.6×	526 0.4×	274	24.2k
Gunnar Kahlmeter	4.4k 0.6×	6.3k 1.5×	2.5k 0.9×	4.0k 1.5×	480 0.3×	204	21.4k
Peter M. Hawkey	4.5k 0.6×	3.6k 0.8×	1.2k 0.5×	3.5k 1.3×	358 0.2×	247	14.9k
Dominique L. Monnet	5.0k 0.7×	5.5k 1.3×	1.7k 0.6×	3.2k 1.2×	366 0.3×	138	20.7k
Christina M. J. E. Vandenbroucke‐Grauls	6.8k 0.9×	4.7k 1.1×	1.4k 0.5×	4.4k 1.7×	470 0.3×	330	20.1k
Louis B. Rice	8.0k 1.1×	6.1k 1.4×	2.7k 1.0×	6.7k 2.6×	964 0.7×	176	27.3k
Brad Spellberg	9.6k 1.3×	7.1k 1.7×	895 0.3×	4.5k 1.7×	717 0.5×	216	21.6k

Countries citing papers authored by Thomas V. Riley

Since Specialization

Citations

This map shows the geographic impact of Thomas V. Riley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas V. Riley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas V. Riley more than expected).

Fields of papers citing papers by Thomas V. Riley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas V. Riley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas V. Riley. The network helps show where Thomas V. Riley may publish in the future.

Co-authorship network of co-authors of Thomas V. Riley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas V. Riley. A scholar is included among the top collaborators of Thomas V. Riley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas V. Riley. Thomas V. Riley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bell, Craig A., et al.. (2025). High prevalence of Clostridioides difficile in retail garden products from two Australian states. Anaerobe. 95. 102987–102987.

Lim, Su‐Chen, et al.. (2025). Clostridioides difficile in Australian dairy farms. Anaerobe. 94. 102983–102983.

Smits, Wiep Klaas, Kevin W. Garey, Thomas V. Riley, & Stuart Johnson. (2025). Clostridioides difficile is a bacterial priority pathogen. Anaerobe. 93. 102965–102965. 1 indexed citations

Imwattana, Korakrit, Papanin Putsathit, Deirdre A. Collins, et al.. (2022). Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017. Microbial Genomics. 8(3). 9 indexed citations

Imwattana, Korakrit, César Rodríguez, Thomas V. Riley, & Daniel R. Knight. (2021). A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile. Microbial Genomics. 7(11). 20 indexed citations

Slimings, Claudia & Thomas V. Riley. (2021). Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update. Journal of Antimicrobial Chemotherapy. 76(7). 1676–1688. 42 indexed citations

Putsathit, Papanin, et al.. (2021). Positional Isomers of Biphenyl Antimicrobial Peptidomimetic Amphiphiles. ACS Medicinal Chemistry Letters. 12(3). 413–419. 9 indexed citations

Putsathit, Papanin, Narelle George, Tony M. Korman, et al.. (2021). Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015–18. Journal of Antimicrobial Chemotherapy. 76(7). 1815–1821. 16 indexed citations

Putsathit, Papanin, M. Hutton, Katherine A. Hammer, et al.. (2021). Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model. Antibiotics. 10(8). 913–913. 8 indexed citations

10.

Putsathit, Papanin, Katherine A. Hammer, Steven M. Wales, et al.. (2019). Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: synthesis, antibacterial evaluation and preliminary mechanism of action studies. European Journal of Medicinal Chemistry. 168. 386–404. 29 indexed citations

11.

Brain, David, Adrian Barnett, Laith Yakob, et al.. (2018). Reducing length of stay to improve Clostridium difficile-related health outcomes. Infection Disease & Health. 23(2). 87–92. 8 indexed citations

12.

Brain, David, Laith Yakob, Adrian Barnett, et al.. (2018). Economic evaluation of interventions designed to reduce Clostridium difficile infection. PLoS ONE. 13(1). e0190093–e0190093. 6 indexed citations

13.

Knight, Daniel R., et al.. (2018). Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound. Scientific Reports. 8(1). 6912–6912. 14 indexed citations

14.

Mulrennan, Siobhain, Anna Tai, Lawson Eng, et al.. (2018). Clostridium difficile infection in cystic fibrosis patients. Pediatric Pulmonology. 53. 393–393. 2 indexed citations

15.

Foster, Niki F., et al.. (2016). Clostridium difficile Infection in Production Animals and Avian Species: A Review. Foodborne Pathogens and Disease. 13(12). 647–655. 37 indexed citations

16.

Riley, Thomas V., et al.. (2014). First report of Erysipelothrix rhusiopathiae‐associated septicaemia and histologic changes in cultured Australian eels, Anguilla reinhardtii (Steindachner, 1867) and A. australis (Richardson, 1841). Journal of Fish Diseases. 38(9). 839–847. 10 indexed citations

17.

Hammer, Katherine A., et al.. (2011). Survey of the Antimicrobial Activity of Commercially Available Australian Tea Tree ( Melaleuca alternifolia ) Essential Oil Products In Vitro. The Journal of Alternative and Complementary Medicine. 17(9). 835–841. 24 indexed citations

18.

Mee, Brian J., et al.. (1997). Legionella longbeachae in Western Australian potting mix (Letter). The Medical Journal of Australia. 166. 2 indexed citations

19.

Riley, Thomas V., et al.. (1992). Susceptibility of Staphylococcus saprophyticus to heavy metals. UWA Profiles and Research Repository (University of Western Australia). 47(185). 55–59. 1 indexed citations

20.

Bowman, R.A. & Thomas V. Riley. (1986). Isolation ofClostridium difficilefrom stored specimens and comparative susceptibility of various tissue culture cell lines to cytotoxin. FEMS Microbiology Letters. 34(1). 31–35. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact